AU2022252094B2 - Crystalline form of a shp2 inhibitor - Google Patents

Crystalline form of a shp2 inhibitor Download PDF

Info

Publication number
AU2022252094B2
AU2022252094B2 AU2022252094A AU2022252094A AU2022252094B2 AU 2022252094 B2 AU2022252094 B2 AU 2022252094B2 AU 2022252094 A AU2022252094 A AU 2022252094A AU 2022252094 A AU2022252094 A AU 2022252094A AU 2022252094 B2 AU2022252094 B2 AU 2022252094B2
Authority
AU
Australia
Prior art keywords
crystalline form
cancer
indene
dihydrospiro
triazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022252094A
Other languages
English (en)
Other versions
AU2022252094A1 (en
Inventor
Katie Keaton BROWN
Aaron Keith GOODWIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AU2022252094A1 publication Critical patent/AU2022252094A1/en
Application granted granted Critical
Publication of AU2022252094B2 publication Critical patent/AU2022252094B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022252094A 2021-04-01 2022-03-30 Crystalline form of a shp2 inhibitor Active AU2022252094B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163169340P 2021-04-01 2021-04-01
US63/169,340 2021-04-01
US202263321902P 2022-03-21 2022-03-21
US63/321,902 2022-03-21
PCT/IB2022/052982 WO2022208408A1 (en) 2021-04-01 2022-03-30 Crystalline form of a shp2 inhibitor

Publications (2)

Publication Number Publication Date
AU2022252094A1 AU2022252094A1 (en) 2023-10-12
AU2022252094B2 true AU2022252094B2 (en) 2024-10-17

Family

ID=81327112

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022252094A Active AU2022252094B2 (en) 2021-04-01 2022-03-30 Crystalline form of a shp2 inhibitor

Country Status (9)

Country Link
US (1) US20240190843A1 (enExample)
EP (1) EP4313307A1 (enExample)
JP (1) JP2024513798A (enExample)
KR (1) KR20230165309A (enExample)
AU (1) AU2022252094B2 (enExample)
BR (1) BR112023019479A2 (enExample)
CA (1) CA3215295A1 (enExample)
MX (1) MX2023011664A (enExample)
WO (1) WO2022208408A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12391708B2 (en) 2019-07-18 2025-08-19 Tapi Croatia Industries Ltd Crystalline Lorlatinib : fumaric acid and solid state form thereof
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001039975A (ja) * 1999-07-26 2001-02-13 Eisai Co Ltd スルホキシド誘導体の結晶およびその製造法
CZ20031098A3 (cs) * 2000-10-20 2003-08-13 Eli Lilly And Company Nová krystalická forma 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]fenoxy)-2-(4-methoxyfenyl)benzo[b]thiofen hydrochloridu
ES2416354T3 (es) * 2005-06-21 2013-07-31 Ajinomoto Co., Inc. Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo
US10287266B2 (en) * 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
PH12019500056B1 (en) * 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
WO2018172984A1 (en) * 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
JP7356414B2 (ja) 2017-09-07 2023-10-04 レヴォリューション・メディスンズ，インコーポレイテッド がんを治療するためのｓｈｐ２阻害剤組成物および方法
SG11202002941WA (en) * 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CA3084058A1 (en) * 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
MX2021002880A (es) 2018-09-14 2021-06-04 Unilever Ip Holdings B V Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes.
IL320682A (en) * 2019-04-02 2025-07-01 Array Biopharma Inc Protein tyrosine phosphatase inhibitors

Also Published As

Publication number Publication date
AU2022252094A1 (en) 2023-10-12
WO2022208408A1 (en) 2022-10-06
EP4313307A1 (en) 2024-02-07
CA3215295A1 (en) 2022-10-06
BR112023019479A2 (pt) 2023-12-05
JP2024513798A (ja) 2024-03-27
MX2023011664A (es) 2023-10-11
KR20230165309A (ko) 2023-12-05
US20240190843A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
US20240190843A1 (en) Crystalline form of a shp2 inhibitor
JP7042812B2 (ja) トリアゾロピリミジン化合物の結晶形態
US7148231B2 (en) [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
US10501466B2 (en) WDR5 inhibitors and modulators
CN117425648A (zh) 作为parp7抑制剂的化合物
EP3686199A1 (en) Fused ring derivative as a2a receptor inhibitor
CN113278012B (zh) 用作激酶抑制剂的化合物及其应用
CN109843874B (zh) 作为parp1、parp2和/或微管蛋白的抑制剂可用于治疗癌症的酞嗪衍生物
TW201733992A (zh) 製備經取代５，６－二氫－６－苯基苯并［ｆ］異喹啉－２－胺之方法
KR102833011B1 (ko) 푸로[3,4-b]피롤-함유 BTK 억제제
WO2023012153A1 (en) Valosin-containing protein (vcp/p97) inhibitors
WO2022002100A1 (zh) 新型苯并咪唑化合物
CN113527311B (zh) Fgfr4抑制剂、组合物及其在药物制备中的用途
AU2023238523B2 (en) Crystalline salt form of a shp2 inhibitor
CN117460725A (zh) Shp2抑制剂的晶型
EP4140985A1 (en) 2-heteroarylaminoquinazolinone derivative
HK40101911A (zh) Shp2抑制剂的晶型
WO2021249324A1 (zh) 烯基嘧啶类化合物、其制备方法与应用
CN115368362A (zh) 作为btk抑制剂的喹喔啉酮类衍生物及其应用
AU2015392050B2 (en) Fumarate of pyridylamine compound and crystals thereof
RU2826000C1 (ru) 3,4-дигидро-2,7-нафтиридин-1,6(2h,7h)-дионы в качестве ингибиторов mek
JP2005162673A (ja) 二環性ピリミジン誘導体
CN121591736A (zh) Hpk1抑制剂及其用途
HK40112682A (zh) Shp2抑制剂的结晶盐形式
CN120344507A (zh) 作为布鲁顿氏酪胺酸激酶抑制剂的新颖嘧啶衍生物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)